This is a new Medtech innovation briefing (MIB) from NICE on the Dexcom G6. This doesn’t give any guidance on when it can be used or if it should be available on the NHS. I don’t normally blog on these, but I thought that this was useful to talk about as patients are likely to be aware of it and may want to discuss it.
One of the big advantages of the Dexcom G6 is that it allows a “hybrid artificial pancreas” to be formed. I will explain this in more detail below. But given this new functionality, I can see that it would be very attractive to patients.
What does the Dexcom G6 do?
It measures interstitial fluid glucose levels. It has a sensor wire that is inserted under the skin. This attaches to a transmitter. The transmitter sends information to a display device via bluetooth. This display device can be a compatible smart device like a phone.
The Dexcom G6, therefore, allows continuous monitoring of glucose levels.
